Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Intellia Therapeutics (NTLA) and Ultragenyx Pharmaceutical (RARE)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Merck & Company (MRK), Intellia Therapeutics (NTLA) and Ultragenyx Pharmaceutical (RARE). Merck & Company (MRK) In a report released today, Courtney Breen from Bernstein maintained a Hold rating on Merck & Company, with a price target of $105.00. The company's shares closed last Friday at $150.33. According to TipRanks.com, Breen is a 5-star analyst with an average return of 21.0% and a 89.1% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Eli Lilly & Co, and Moderna. ;'> Currently, the analyst consensus on Merck & Company is a Strong Buy with an average price target of $154.88, a 2.7% upside from current levels. In a report issued on August 25, RBC Capital also maintained a Hold rating on the stock with a $150.00 price target. See today's best-performing stocks on TipRanks >> Intellia Therapeutics (NTLA) In a report issued on September 4, Joseph Thome from TD Cowen maintained a Buy rating on Intellia Therapeutics. The company's shares closed last Friday at $12.74. According to TipRanks.com, Thome is a 5-star analyst with an average return of 24.0% and a 54.7% success rate. Thome covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Arrowhead Pharmaceuticals, and Mirum Pharmaceuticals. ;'> Currently, the analyst consensus on Intellia Therapeutics is a Moderate Buy with an average price target of $20.90. Ultragenyx Pharmaceutical (RARE) In a report issued on September 3, Joseph Schwartz from Leerink Partners maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $33.00. The company's shares closed last Friday at $15.30. According to TipRanks.com, Schwartz is a 5-star analyst with an average return of 32.9% and a 54.1% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Edgewise Therapeutics, Quince Therapeutics, and Gossamer Bio. ;'> The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ultragenyx Pharmaceutical with a $27.47 average price target, representing a 77.5% upside. In a report issued on August 20, William Blair also initiated coverage with a Buy rating on the stock. Read More on MRK: Disclaimer & DisclosureReport an Issue